HIV/AIDS

More People Worldwide Now Know Their HIV Status

More People Worldwide Now Know Their HIV Status

However, millions of people still do not know their status and do not have a suppressed viral load.

Biologic Agents Used to Treat Patients With Psoriasis and HIV Infection

Biologic Agents Used to Treat Patients With Psoriasis and HIV Infection

By

Investigators evaluated the safety and effectiveness of conventional therapy with biologic immunosuppressive drugs to treat patients with HIV infection and psoriasis.

Barriers to Prevention, Eradication of HIV Remain Despite Numerous Advances

Barriers to Prevention, Eradication of HIV Remain Despite Numerous Advances

By

Since the first clinical observation of HIV/AIDS in 1981, some 35.4 million people have died from AIDS-related illnesses.

Elevated PCSK9 Levels Associated With Coronary Endothelial Dysfunction in PLWHIV

Elevated PCSK9 Levels Associated With Coronary Endothelial Dysfunction in PLWHIV

By

Increased proprotein convertase subtilisin/kexin type 9 (PCSK9) levels in people with HIV may be related to abnormal coronary endothelial function.

Lamivudine/Tenofovir Disoproxil Approved for the Treatment of HIV-1 Infection

Lamivudine/Tenofovir Disoproxil Approved for the Treatment of HIV-1 Infection

By

The FDA has approved Temixys tablets for use in combination with other antiretroviral agents for the treatment of HIV-1 infection in patients weighing ≥35kg.

Increased Risk of Meningococcal Disease in Men Who Have Sex With Men

Increased Risk of Meningococcal Disease in Men Who Have Sex With Men

By

Men who have sex with men have an increased risk of meningococcal disease, however, this risk is under-ascertained and improved surveillance is needed.

USPSTF Suggests Universal HIV Screening, PrEP for High-Risk Patients

USPSTF Suggests Universal HIV Screening, PrEP for High-Risk Patients

Screening recommended for those ages 15 to 65 years, including pregnant women.

Increased Risk for First and Second Primary Cancers in Patients With HIV/AIDS

Increased Risk for First and Second Primary Cancers in Patients With HIV/AIDS

By

Increased cancer prevention, screening, and treatment are needed for people living with HIV both before and after an initial cancer diagnosis.

New Single-Vial Formulation of Tesamorelin Approved to Treat Excess HIV-Related VAT

New Single-Vial Formulation of Tesamorelin Approved to Treat Excess HIV-Related VAT

By

The new "F4" formulation is 4 times more concentrated than the version currently available on the market.

Labeling for Two HIV Drugs Updated With Safety, PK Data for Pregnant Patients

Labeling for Two HIV Drugs Updated With Safety, PK Data for Pregnant Patients

By

The "8.1 Pregnancy" and "12.3 Pharmacokinetics" sections have been updated with data showing no increase in the risk of overall major birth defects with 1st trimester exposure for rilpivirine.

ART Initiated Pre-Pregnancy Lowers Hospitalization due to Infection in HIV-Exposed Infants

ART Initiated Pre-Pregnancy Lowers Hospitalization due to Infection in HIV-Exposed Infants

By

ART prior to becoming pregnant was linked with reduced risk for hospitalization because of infections in seronegative infants who are exposed to HIV.

Earlier Intervention May Have Lessened HIV Outbreak in Indiana

Earlier Intervention May Have Lessened HIV Outbreak in Indiana

By

Ensuring access to HIV services and harm-reduction interventions earlier could substantially reduce HIV incidence over the course of an actual outbreak.

High-Coverage Rollout of PReP Tied to Drop in HIV Diagnoses

High-Coverage Rollout of PReP Tied to Drop in HIV Diagnoses

A rapid, targeted, high-coverage rollout of HIV PrEP is associated with a decrease in HIV diagnoses among high-risk MSM.

Infant HIV Infection Ups Risk for Congenital CMV Infection

Infant HIV Infection Ups Risk for Congenital CMV Infection

HIV-exposed infants have high rates of congenital cytomegalovirus (cCMV) infection, and in utero HIV infection seems to be a major risk factor for cCMV.

Contraceptive Use Inadequate Among Young Women With HIV

Contraceptive Use Inadequate Among Young Women With HIV

By

Effective contraception, condoms, and dual method use was inadequately low in a cohort of young HIV-positive women.

Advance Care Planning Lowers Symptoms in Teens With HIV

Advance Care Planning Lowers Symptoms in Teens With HIV

Family-centered pediatric advance care planning may result in fewer symptoms, less suffering.

Hispanics With HIV Face Higher Risk for HPV-Related Cancer

Hispanics With HIV Face Higher Risk for HPV-Related Cancer

But five-year survival was above 50 percent among HIV-infected Hispanics across HPV-related cancer types.

Conflicting Findings of EBV-Biomarker Use in HIV-Related Lymphomas

Conflicting Findings of EBV-Biomarker Use in HIV-Related Lymphomas

By

Conflicting findings regarding the association between plasma Epstein-Barr virus load in PLWHIV and HIV-related lymphomas shows a need for assessment of who benefits from an optimal management of HIV infection and comorbidities.

Bioavailability of Coformulated ART Dispersible Tablet Comparable to Standard Formulation

Bioavailability of Coformulated ART Dispersible Tablet Comparable to Standard Formulation

By

A dispersible fixed-dose combination tablet formulation of abacavir/dolutegravir/lamivudine for the treatment of HIV-1 had higher bioavailability of dolutegravir compared to the nondispersible film-coated tablet.

470 Percent Increase in HIV PrEP Use in US, 2014 to 2016

470 Percent Increase in HIV PrEP Use in US, 2014 to 2016

From 2014 to 2016 there was an increase in the annual number of HIV preexposure prophylaxis (PrEP) users in the United States.

More Socioeconomic Challenges for Hispanic Women With HIV

More Socioeconomic Challenges for Hispanic Women With HIV

Hispanic/Latino women with HIV infection face more socioeconomic and language challenges than men, but the clinical outcomes are similar.

Viral Suppression in Children on ART Identified Via Quantitative HIV Antibody Levels

Viral Suppression in Children on ART Identified Via Quantitative HIV Antibody Levels

By

For children receiving , HIV-1-specific antibody levels can be useful markers for measuring viral suppression or for low residual cell-associated HIV-1 DNA levels.

Retention in HIV Care Drops Steadily After Prison Release

Retention in HIV Care Drops Steadily After Prison Release

For criminal justice-involved persons living with HIV, sustained retention in care decreases over time post-release.

Glecaprevir/Pibrentasvir Is Safe, Efficacious for HCV/HIV-1 Coinfection

Glecaprevir/Pibrentasvir Is Safe, Efficacious for HCV/HIV-1 Coinfection

By

Analysis of 2 phase 3 clinical trials evaluating the safety/efficacy of glecaprevir/pibrentasvir in people with HCV coinfected with HIV-1 found an overall sustained virologic response of 98% at week 12 of treatment in those with or without cirrhosis.

Once Daily Single-Tablet HIV Regimen Safe and Effective

Once Daily Single-Tablet HIV Regimen Safe and Effective

By

Once-daily single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in adults who have virologic suppression of HIV-1 infection has a high efficacy and safety profile.

Common Antiretrovirals Have Same Likelihood of Certain Disorders After Initiation

Common Antiretrovirals Have Same Likelihood of Certain Disorders After Initiation

By

Incidence of body fat redistribution/accumulation, pancreatic disorders, musculoskeletal disorders, IRIS, severe systemic rash, and HSR did not differ among common prescribed antiretrovirals.

A Single Combination Tablet Suppresses HIV Load Through 48 Weeks

A Single Combination Tablet Suppresses HIV Load Through 48 Weeks

By

A combination single tablet once-a-day regimen of doravirine/lamivudine/tenofovir disoproxil fumarate demonstrated non-inferiority and no significant adverse events when compared with continuation of established antiretroviral therapy in adults infected with HIV-1.

Continued Noninferiority of Doravirine to Efavirenz at Week 96

Continued Noninferiority of Doravirine to Efavirenz at Week 96

By

The week 96 results of the DRIVE-AHEAD phase 3 noninferiority trial support noninferiority of doravirine to efavirenz in treatment-naive adults with HIV-1.

In Utero Antiretroviral Exposure Associated With Higher Neurological Risk

In Utero Antiretroviral Exposure Associated With Higher Neurological Risk

By

Children who are HIV-exposed, but uninfected, demonstrated a higher risk of adverse neurologic events during infancy and early childhood associated with ART exposure in-utero.

HIV Infection Diagnoses on the Rise in Young Homosexual Men

HIV Infection Diagnoses on the Rise in Young Homosexual Men

Number of HIV diagnoses in those aged 13 to 29 four times higher than those age 50 years or older.

Sign Up for Free e-newsletters